Key Benefits:
President of the Republic,
On the report of the Prime Minister and the Minister for Foreign Affairs,
Considering the Constitution, in particular articles 52 to 55;
Vu le Decree No. 53-192 of 14 March 1953 amended on the ratification and publication of international commitments undertaken by France;
Vu le Decree No. 2007-503 of 2 April 2007 publishing the international convention against doping in sport (two annexes), adopted in Paris on 19 October 2005;
Vu le Decree No. 2008-35 of 10 January 2008 publishing the amendment to the annex to the Convention against Doping, adopted by the follow-up group at its 26th meeting on 12 November 2007 in Madrid;
Vu le Decree No. 2009-93 of 26 January 2009 having published the amendment to the annex to the convention against doping, adopted on 13 November 2008 in Strasbourg, and Appendix 1 of the international convention against doping in sport, adopted in Paris on 17 November 2008;
Vu le Decree No. 2010-134 of 10 February 2010 publishing the amendment to the annex to the convention against doping, adopted on 18 November 2009 in Strasbourg, and Appendix 1 of the international convention against doping in sport, adopted in Paris on 28 October 2009;
Vu le Decree No. 2010-1578 of 16 December 2010 publishing the amendment to the annex to the convention against doping, adopted on 8 and 9 November 2009 in Strasbourg, and Appendix 1 of the international convention against doping in sport, adopted in Paris on 17 November 2010;
Vu le Decree No. 2011-1947 of 23 December 2011 publishing the amendment to the annex to the convention against doping, adopted on 7 November 2011 in Strasbourg, and Appendix 1 of the international convention against doping in sport, adopted in Paris on 14 November 2011,
Decrete:
The amendment to the appendix to the convention against doping, adopted in Paris on 13 November 2012, and to Annex 1 of the international convention against doping in sport, adopted in Paris on 12 November 2012, will be published in the Official Journal of the French Republic.
The Prime Minister and the Minister for Foreign Affairs are responsible for the execution of this Order, which will be published in the Official Journal of the French Republic.
A M E N D E M E N T
AT THE ANNEX OF THE CONVENTION AGAINST DOPAGE, ADOPTED at PARIS on 13 NOVEMBER 2012, AND ANNEX 1 OF THE INTERNATIONAL CONVENTION AGAINST DOPAGE IN THE SPORT, ADOPTED at PARIS on 12 NOVEMBER 2012
LIST OF SUBSTANCES AND METHODS
IN THE SPORT (LIST 2013)
CODE MONDIAL ANTIDOPAGE
LIST OF PROHIBITIONS 2013
STANDARD INTERNATIONAL
This list will come into force on January 1, 2013
In accordance with Article 4.2.2 of the World Anti-Doping Code, all prohibited substances must be considered as "specified substances" except substances in classes S1, S2, S4.4, S4.5, S6.a, and prohibited methods M1, M2 and M3.
SUBSTANCES AND INTERNATIONAL METHODS
EN PERMANENCE (EN ET HORS COMPÉTITION)
SUBSTANCES INTERDITES
S0. SUBSTANCES NON APPROVED
Any pharmacological substance not included in a section of the List below and which is not currently approved for therapeutic use in humans by a regulatory health authority (e.g., health regulatory authority). preclinical or clinical development drugs or drugs that are no longer available, medicines in a manner, approved substances only for veterinary use) is permanently prohibited.
S1. ANABOLISANT AGENTS
Anabolic agents are forbidden.
1. Androgenic anabolic steroids (SAA)
a. Exogenous SAA*, including:
1-androstènediol (5-androst-1-ène-3,17-diol) ; 1-androstènedione (5-androst-1-ène-3,17-dione); bolandiol (estr-4-ène-3,17-diol); bolasterone; boldénone; boldione (androsta-1,4-diène-3,17-dione); calusterone; enclosedbol; danazol ([1,2]oxazolo[4',5':2,3]pregna-4-ène-20-yn-17-ol); dehydrochlormethyltestosterone (4-chloro-17-hydroxy-17-methylandrosta-1,4-diène-3-one); deoxymethyltestosterone (17-methyl-5-androst-2-ene-17-ol); drostanolone; ethylestrenol (19-norprégna-4-ène-17-ol) ; fluoxymesterone ; formationbolone ; ferazabol (17-methyl-[1,2.5]oxadiazolo[3',4':2,3]-5-androstane-17-ol); gestrinone; 4-hydroxytestosterone (4,17-dihydroxyandrost-4-ene-3-one) ; mestanolone ; mesterolone ; méténolone ; methanediénone (17-hydroxy-17-methylandrosta-1,4-diène-3-one); methandriol; methasterone (17-hydroxy-2, 17-dimethyl-5-androstane-3-one); methyldiénolon (17-hydroxy-17-methylestra-4,9-diène-3-one) ; methyl-1-testosterone (17-hydroxy-17-methyl-5-androst-1-ène-3-one); methylnortestosterone (17-hydroxy-17-methylestr-4-ene-3-one); methyltestosterone; metribolone (methyltriènolone, 17-hydroxy-17-methylestra-4,9,11-triène-3-one); mibolone; nandrolone; 19-norandrostendione (estr-4-ene-3,17-dione); norboletone; norclostebol; Norethandrolone ; oxabolone ; oxandrolone ; oximesterrone; oxymetholone; prostanozol (17[(tétrahydropyrane-2-yl)oxy]-l'H-pyrazolo[3,4:2,3]-5-androstane) ; quinbolone ; stanozolol ; stenbolone ; 1-testosterone (17-hydroxy-5-androst-1-ène-3-one) ; tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17-prégna-4,9,11-triène-3-one); trenbolone (17-hydroxyestr-4,9,11-trine-3-one); and other substances having a similar chemical structure or a similar biological effect(s).
b. Endogenous SAA** by exogenous administration:
androstènediol (androst-5-ène-3,17-diol) ; androstènedione (androst-4-ène-3,17-dione) ; dihydrotestosterone (17-hydroxy-5-androstan-3-one) ; prasterone (dehydroepandrosterone, DHEA, 3-hydroxyandrost-5-ène-17-one) ; testosterone ; and the following metabolites and isomers, including without limitation:
5-androstane-3,17-diol; 5-androstane-3,17-diol; 5-androstane-3,17-diol; 5-androstane-3,17-diol; androst-4-ene-3,17-diol; androst-4-ene-3,17-diol; androst-4-ene-3,17-diol; androst-5-ene-3,17-diol; androst-5-ene-3,17-diol; androst-5-ene-3,17-diol; 4-androstènediol (androst-4-ène-3,17-diol) ; 5-androstènedione (androst-5-ène-3,17-dione) ; epi-dihydrotestosterone ; epitestosterone ; etiocholanolone ; 3-hydroxy-5-androstan-17-one; 3-hydroxy-5-androstan-17-one; 7-hydroxy-DHEA; 7-hydroxy-DHEA; 7-keto-DHEA; 19-norandrosterone; 19-norétiocholanolone.
2. Other anabolic agents, including but not limited to:
Clenbuterol, selective modulators of androgenic receptors (SARMs), tibolone, zéranol, zilpatrol.
For the purposes of this document:
* "exogenous" means a substance that cannot usually be produced naturally by the human body.
** "endogenous" means a substance that can be produced naturally by the human body.
S2. PEPTIDICAL HORMONS, CROISSANCE FACTORS AND APPROVAL SUBSTANCES
The following substances and their release factors are prohibited:
1. Erythropoiesis stimulant agents [e.g. erythropoietin (EPO), darbepoetine (DEPO), methoxy polyethylene glycol-epoetin beta (CERA), petginesatide (Hematide), stabilizing factors inductible by hypoxia (HIF));
2. chorionic Gonadotrophin (CG) and luteinizing hormone (LH), prohibited in male sports only;
3. Corticotrophines;
4. Growth Hormone (GH), growth factor similar to insulin-1 (IGF-1), growth factor derived from platelets (PDGF), endothelial vascular growth factor (VEGF), hepatocyte growth factor (HGF), fibroblastic growth factors (FGF), mechanical growth factors (MGF), as well as any other growth factor influencing
and other substances having a similar chemical structure or a similar biological effect(s).
S3. BÊTA-2 AGONISTS
All beta-2 agonists, including all their optical isomers (e.g. d- and l-) if applicable ― are prohibited, except salbutamol inhaled (maximum 1,600 micrograms per 24 hours), inhaled formoterol (maximum dose of 54 micrograms per 24 hours) and salmétérol administered by inhalation according to the recommended diagrams
The presence in the urine of salbutamol at a concentration greater than 1000 ng/mL or formoterol at a concentration greater than 40 ng/mL will be presumed not to be an intentional therapeutic use and will be considered as a result of abnormal analysis, unless the athlete proves by a controlled pharmacokinetic study that this abnormal result is the consequence of the use of a maximum dose by inhalation.
S4. HORMONAL AND METHODS
The following substances are prohibited:
1. Aromatase inhibitors, including but not limited to: aminoglutethhimide, anastrozole, androsta-1,4,6-trine-3,17-dione (androstatrenedione), 4-androstène-3,6,17 trione (6-oxo), exemestane, formstane, letrozole, testolactone.
2. Selective modulators of receptors to estrogen (SERM), including without limitation: raloxifen, tamoxifen, toremifen.
3. Other anti-estrogogenic substances, including but not limited to: clomifene, cyclofenil, fulvestrant.
4. Modifying agents of myostatin function(s), including without limitation: myostatin inhibitors.
5. Metabolic modulators:
(a) Insulins;
(b) The receptor agonists activated by the proliferators of the peroxysomes (PPAR) (e.g. GW 1516) and the agonists of the PPAR-protein kinase axis activated by the AMP (AMPK) (e.g. AICAR).
S5. DIURETIC AND OTHER MASQUANTS
Agents are forbidden. They include:
Diuretics, desmopressin, probenecide, plasma substitutes (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl stardon and mannitol), and other substances with similar biological effect(s).
The local administration of felypressin in dental anesthesia is not prohibited.
Diuretics include:
Acetazolamide, amiloride, bumetanide, canrenone, chlortalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamten, and other substances with a similar chemical structure or
The use in competition, and out of competition if applicable, of any quantity of a substance being subject to a threshold level (i.e. formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other masking agent requires the issuance of an authorization of use for specific therapeutic purposes for this substance, in addition to that
METHODS
M1. MANIPULATION OF SANGUAGE OR SANGUAGE
The following is prohibited:
1. Administration or reintroduction of any amount of autologous blood, homologous or heterologist, or red blood cells of any origin in the circulatory system.
2. Artificial improvement in the consumption, transport or release of oxygen, including, but not limited to, perfluorinated chemicals, efaproxiral (RSR13) and modified hemoglobin products (e.g. blood substitutes based on hemoglobin, reticulated hemoglobin products), but excluding oxygen supplementation.
3. Any intravascular manipulation of blood or blood component(s) by physical or chemical methods.
M2. CHEMICAL AND PHYSICAL MANIPULATION
The following is prohibited:
1. Falsification, or attempted falsification, in order to alter the integrity and validity of samples collected during doping control. This category includes, but is not limited to, the substitution and/or alteration of urine (e.g. proteases).
2. Intravenous infusions and/or injections of more than 50 mL per 6-hour period, except those legitimately received in hospital admissions or in clinical examinations.
M3. GENERAL DOPAGE
The following, having the potential capacity to improve sports performance, is prohibited:
1. Transfer of nucleic acid polymers or nucleic acid analogs;
2. Use of normal or genetically modified cells.
SUBSTANCES AND METHODS
IN COMPETITION
In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited in competition:
SUBSTANCES INTERDITES
S6. STIMULANTS
All stimulants, including all optical isomers (e.g. d- and l-) where applicable, are prohibited, with the exception of topical application imidazole derivatives and stimulants in the 2013 Monitoring Program*.
Stimulants include:
a: Stimulants not specified:
Adrafinil, amphetamine, mephenamine, phenamine A stimulant that is not specifically named in this section is a specified substance.
b: Specified stimulants (examples):
Adrenaline**, cathine***, ephedrine****, etamivan, etiléfrine, fenbutrazate, fencamfamine, heptaminol, isometalamine, levmetamfenoxate, methylephedrine****, methylhexaneamine (dimethylpentylamine), methylphenidate, nicethamide
* Substances in the 2013 Surveillance Program (bupropion, caffeine, nicotine, phenylpropanolamine, pipradrol, synephrine) are not considered prohibited substances.
** Local use (e.g. nasal or ophthalmological path) of adrenaline or co-administration with local anesthetics are not prohibited.
*** Cathine is prohibited when its concentration in the urine exceeds 5 micrograms per millilitre.
**** Ephedrine and methylephedrine are prohibited when their respective concentrations in urine exceed 10 micrograms per millilitre.
***** The pseudoephedrine is prohibited when its concentration in the urine exceeds 150 micrograms per millilitre.
S7. NARCOTIQUES
The following is prohibited:
Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocin, penthidine.
S8. CANNABINOÏDES
Natural Δ9-tetrahydrocannabinol (THC) (e.g. cannabis, haschisch, marijuana) or synthetic, and cannabimimetics (e.g. "Spice", JWH018, JWH073, HU-210) are prohibited.
S9. GLUCOCORTICOÏDES
All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal.
SUBSTANCES INTERDITES
IN SPORT REQUIREMENTS
P1. ALCOOL
Alcohol (ethanol) is prohibited in competition only in the following sports. The detection will be performed by ethylometry and/or blood analysis. The violation threshold (hematological values) is 0.10 g/L.
Aeronautics (FAI).
Automobile (FIA).
Karate (WKF).
Motorcycling (FIM).
Motonautique (UIM).
Archery (FITA).
P2. BÊTA-BLOQUANTS
Unless otherwise stated, beta-blockers are prohibited in competition only in the following sports:
Automobile (FIA).
Leg (all disciplines) (WCBS).
Darts (WDF).
Golf (IGF).
Ski (FIS) for ski jump, freestyle/halfpipe jump and halfpipe/big air snowboard.
Shooting (ISSF, IPC) (also banned out of competition).
Archery (FITA) (also banned out of competition).
Beta-blockers include but are not limited to:
Acebutolol, alprenolol, aténolol, betaxolol, bisoprolol, bunolol, cartéolol, carvedilol, celiprolol, esmolol, labétalol, lévobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, proptalranolol, so
Done on 19 December 2012.
François Hollande
By the President of the Republic:
The Prime Minister,
Jean-Marc Ayrault
Minister of Foreign Affairs,
Laurent Fabius
